Results 301 to 310 of about 531,046 (373)

Nuclear Magnetic Resonance Solution Structure of the Recombinant Fragment Containing Three Fibrin-Binding Cysteine-Rich Domains of the Very Low Density Lipoprotein Receptor. [PDF]

Biochemistry, 2018
Banerjee K, Yakovlev S, Gruschus JM, Medved L, Tjandra N.   +4 more
europepmc   +1 more source

5‐Methylcytosine Analysis of miRNAs in Minimal Change Disease

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Minimal change disease (MCD) is a glomerular disorder, which is the most common cause of nephrotic syndrome in children. Additionally, the prevalence of MCD in adults has been increasing in recent years. During protein synthesis, noncoding RNAs can be regulated through a variety of modifications, which helps preserve biological diversity and ...
Huiyi Zeng, Dandan Li, Yunyi Li, Chen Yun, Xinzhou Zhang, Wenyu Gong, Mengyun Xiao, Haitao Li, Zhipeng Zeng, Ruqi Tan, Yishen Yang, Shaodong Luan, Yong Dai, Lianghong Yin, Donge Tang   +14 more
wiley   +1 more source

Very-Low-Density Lipoprotein of Metabolic Syndrome Modulates Gap Junctions and Slows Cardiac Conduction. [PDF]

Sci Rep, 2017
Lee HC, Chen CC, Tsai WC, Lin HT, Shiao YL, Sheu SH, Wu BN, Chen CH, Lai WT.   +8 more
europepmc   +1 more source

Very low and low density lipoprotein synthesis and secretion by the human hepatoma cell line Hep-G2: effects of free fatty acid.

, 1988
Jeff L. Ellsworth, Sandra K. Erickson, A D Cooper   +2 more
openalex   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims Vutiglabridin (HSG4112) is a novel drug under clinical development for antiobesity treatment. This study aimed to evaluate the pharmacokinetics (PKs) and safety of vutiglabridin after multiple oral administrations in healthy Korean female and obese subjects and explore short‐term pharmacodynamic (PD) responses.
Sooyoun Lee, Hyun Chul Kim, Young Ran Yoon, In‐Jin Jang, Sang‐Ku Yoo, Kyung‐Sang Yu   +5 more
wiley   +1 more source

Functional Differences of Very-Low-Density Lipoprotein Receptor Splice Variants in Regulating Wnt Signaling. [PDF]

Mol Cell Biol, 2016
Chen Q, Takahashi Y, Oka K, Ma JX.
europepmc   +1 more source

Biomaterial design strategies for enhancing mitochondrial transplantation therapy

BMEMat, EarlyView.
Biomaterials to facilitate mitochondrial transplantation therapy: biomaterials as barriers to protect mitochondria from pathophysiological microenvironments, like osmotic stress caused by the excessive concentration of calcium ion, reactive oxygen species, and advanced glycation end products; biomaterials integrating with biochemical cues to improve ...
Shaoyang Kang, Yushan Zhang, Hang Li, Sirui Peng, Donghao Lyu, Chunxiao Zhou, Sheng Ding, Zujian Feng, Pingsheng Huang, Chuangnian Zhang, Hongjun Wang, Deling Kong, Weiwei Wang   +12 more
wiley   +1 more source

In Vitro Analysis of the Very-Low Density Lipoprotein Export from the Trans-Golgi Network. [PDF]

Curr Protoc Cell Biol, 2015
Siddiqi SA.
europepmc   +1 more source

Nanomaterial‐based immune therapeutic strategies in neurodegenerative diseases

BMEMat, EarlyView.
This review highlights the immunomodulatory potential of nanomaterials (NMs) in treating neurodegenerative diseases (NDs). It focuses on their roles in regulating innate and adaptive immune responses to maintain immune homeostasis. By providing insights into these mechanisms, the review lays the groundwork for innovative NMs therapeutic strategies to ...
Xinru Zhou, Jia Liu, Shulin Lai, Suhan Yin, Bingmin Luo, Longquan Shao, Yiyuan Kang   +6 more
wiley   +1 more source